RT Journal Article
T1 Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.
A1 Sokolowska, Milena
A1 Rovati, G Enrico
A1 Diamant, Zuzana
A1 Untersmayr, Eva
A1 Schwarze, Jürgen
A1 Lukasik, Zuzanna
A1 Sava, Florentina
A1 Angelina, Alba
A1 Palomares, Oscar
A1 Akdis, Cezmi A
A1 O'Mahony, Liam
A1 Jesenak, Milos
A1 Pfaar, Oliver
A1 Torres, Maria Jose
A1 Sanak, Marek
A1 Dahlen, Sven-Erik
A1 Woszczek, Grzegorz
K1 COVID-19
K1 LTRA
K1 NSAID
K1 Asthma
K1 Biologicals
AB Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.
PB Wiley
YR 2022
FD 2022-02-11
LK http://hdl.handle.net/10668/19899
UL http://hdl.handle.net/10668/19899
LA en
NO Sokolowska M, Rovati GE, Diamant Z, Untersmayr E, Schwarze J, Lukasik Z, et al. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19. Allergy. 2022 Aug;77(8):2337-2354
DS RISalud
RD Apr 10, 2025